

## Clinical Champion Update

Date: 7/18/22

Subject: Diabetes

We would like to update you on a new medication available for the treatment of Type 2 Diabetes. Mounjaro (tirzepatide) is a once weekly injectable in the new class of “GLP-1 and GIP receptor agonist.” It is currently the only medication in this class. Because it works on two incretin receptors (instead of just GLP-1), it is deemed superior to GLP-1 class leader semaglutide in A1c reduction and weight loss. Trials are underway to evaluate its role in lowering cardiovascular risk. Please see the attached slide presentation for information on prescribing. A new order set has been created for you to use titled, “Diabetes\_StartMounjaro.” This is not approved for weight loss/morbid obesity only – the patient must have T2DM.

Please also note the last A1c for all diabetic patients you have a visit with for any reason. All patients should already have their first A1c for the year. Consider a POC A1c in any patient who is not up to date. Many patients plan on going to the lab and then do not follow through for any number of reasons. Our rates are improving but we are not yet at goal.

